Tobira Therapeutics Inc. Announce Presentation of TBR-652 Data at European AIDS Conference
To keep up to date with news from this category use our
NOVAVAX to Present at the Influenza Congress USA 2009
ROCKVILLE, MD (November 11, 2009) - Novavax, Inc. (NASDAQ: NVAX) a clinical-stage vaccine company, announced today that John Trizzino, Senior Vice President, International and Government Alliances, will be presenting at...
Mobidiag Launches Rapid DNA Microarray Technology for Diagnostics of Bone and Joint Infections
Birmingham, United Kingdom, November 11, 2009 - Finnish molecular diagnostics company Mobidiag releases rapid microarray solution for identifying bacteria responsible for bone and joint infections (BJIs). Enhancing the...
Pandemic 2009 Influenza Update: US FDA approves GSK's pandemic H1N1 vaccine
10 November 2009, London UK & Philadelphia US -- GlaxoSmithKline (GSK) today announced that the US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for its unadjuvanted...
Advanced Life Sciences Announces Third Quarter 2009 Financial Results
CHICAGO, Nov. 10-- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of...
GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries
Tuesday 10 November 2009, London, UK -- GlaxoSmithKline (GSK) today announced that it has signed an agreement with the World Health Organization (WHO) to donate 50 million doses of its adjuvanted pandemic H1N1 influenza...
Foamix Expands International Patent Protection for its Emollient Foam Platform
Rehovot (Israel), November 4, 2009 -- Foamix Ltd., a leading developer of topical foams for dermatological and gynecological use, announced today that it has been awarded Mexican Patent Registration No. 268451 entitled...
Antigenics Provides Details On GlaxoSmithKline's Pivotal Malaria Vaccine Trial With QS-21 Adjuvant
LEXINGTON, MA - November 4, 2009 - Antigenics, Inc. (NASDAQ: AGEN) today indicated that GlaxoSmithKline's (GSK) Phase III malaria vaccine clinical trial, containing Antigenics' QS-21 Stimulon
AlphaVax Progresses a Prophylactic HSV Vaccine
November 04, 2009--The development of an effective prophylactic vaccine against herpes simplex virus (HSV) is a key product opportunity for which the AlphaVax vector platform is ideally suited. [HSV Program]. Recently,...
Nabi Biopharmaceuticals Completes Sale of PentaStaph(TM) to GlaxoSmithKline PLC
ROCKVILLE, Md., November 4, 2009 -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced that it has completed the sale of PentaStaph(TM) (Pentavalent S. aureus Vaccine) and related assets to GlaxoSmithKline PLC (GSK). The...
Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
CAMBRIDGE, Mass.-- November 3, 2009-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through Toll-like Receptor 9...
Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
CAMBRIDGE, Mass., November 3, 2009 -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today...
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care
Tuesday 3 November 2009 -- Today, ViiV Healthcare, a new specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer, was officially launched. Dr Dominique Limet, the Chief Executive Officer of ViiV...
Novavax Reports Positive Data for its Trivalent Seasonal Influenza (VLP) Vaccine Candidate in a Second Phase II Study
ROCKVILLE, MD (November 2, 2009) - Novavax, Inc. (NASDAQ: NVAX) a clinical-stage vaccine company, announced today that the Company made a poster presentation on the "Safety and Immunogenicity of a Recombinant Trivalent...
Additional Data from Fidaxomicins Phase 3 Study for Clostridium difficile infection (CDI) Presented at IDSA Annual Meeting
SAN DIEGO- October 31, 2009 - Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious...
Cancer trials and good manufacturing practice
October 30, 2009--An article in Friday's issue of the Danish medical journal 'Dagens Medicin' accuses the Danish Medicines Agency of delaying the development of new cancer medicine. The specific case involves an...
Pandemic (H1N1) 2009 Influenza Update: Experience of GSK's H1N1 adjuvanted vaccine, Pandemrix(TM), and preliminary paediatric results
October 23, 2009 -- GlaxoSmithKline (GSK) today announced that, to date, more than 150,000 people have received GSK's pandemic H1N1 vaccine, Pandemrix(TM), as part of Government initiated vaccination programmes across...
BioServe Selected by Government of A.P. India to Test H1N1 (Swine Flu) Patients
Beltsville, MD; and Hyderbad, AP, India, October 21, 2009 - BioServe(TM), a leading provider of clinical bio-samples and research services, today announced that it has been selected by the Government of the State of...
Crucell HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris
Leiden, The Netherlands (October 21, 2009) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that preliminary results of the Phase I study of its HIV vaccine were...
Two new appointments to BioAlliance Pharma's Supervisory Board in phase with the company's development
Paris, October 21, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members.
Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
Durham, NC and Paris, France- October 21, 2009 -- Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing...
Novavax and Xcellerex Announce Collaboration to Develop Large-scale Manufacturing Process for 2009 H1N1 Influenza VLP Vaccine
Rockville, MD and Marlborough, MA - October 21, 2009 - Novavax, Inc. (NASDAQ: NVAX) and Xcellerex, Inc. has entered into a strategic collaboration to accelerate the development of Novavax's vaccine manufacturing process...
KaloBios' KB001 Antibody Shows Encouraging Safety and Activity in New Approach to Fighting Pseudomonas Infection in Cystic Fibrosis Patients
SOUTH SAN FRANCISCO, CA (October 15, 2009) - Phase 1/2 clinical trial results with KB001, a Humaneered(TM), high-affinity antibody fragment under development by KaloBios Pharmaceuticals, Inc. in cystic fibrosis patients...
BioAlliance Pharma announces Phase I trial for Fentanyl Lauriad
Paris, October 12, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency...
MedaSorb Technologies Corporation Raises $1.3M in Series B Warrant Exercise
MONMOUTH JUNCTION, NJ-- 10/09/09 - MedaSorb Technologies Corporation (OTC.BB:MSBT - News) and its wholly-owned subsidiary CytoSorbents, Inc., announced that it has raised $1.3 million in the exercise of the warrant...
Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
October 07, 2009 -- Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription...
Aphios Awarded NIH ARRA Challenge Grant for Pathogen Inactivation Technology for Blood Products
September 30, 2009 -- Aphios Corporation today announced that it has been awarded a RC-1 Challenge grant (No. 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health's...
iBio Completes $3 Million Private Placement
NEWARK, DE - September 10, 2009 - iBio, Inc. (OTCBB: IBPM) today announced a private placement of approximately $3 million of its common stock principally to current stockholders who previously purchased the Company's...
Tarix Pharmaceuticals receives IND to treat HIV patients with persistently low CD4 counts
Brookline, MA, March 21, 2008 -- Tarix Phamaceuticals announced that it has received an approval of an IND to begin a Phase Ia dose escalation study to evaluate the safety of TXA127 in HIV patients maintained on HAART...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
